Second Auto Hematopoietic Cell Transplants Well Tolerated in Multiple Myeloma

Share this content:

(ChemotherapyAdvisor) – In selected myeloma patients, a second autologous hematopoietic cell transplant (auto-HCT) for salvage therapy is well tolerated, with acceptable toxicity, according to a team of US-based researchers. This conclusion is based on a study entitled “Durable remission with salvage second autotransplants in patients with multiple myeloma,” which is published in the July 15 issue of Cancer.

In this study, the investigators aimed to identify the role of salvage auto-HCT for relapsed patients. To accomplish this feat, the investigators conducted a retrospective analysis of 44 myeloma patients who had previously received a second auto-HCT as salvage therapy.

The investigators reported the following results for patients after salvage chemotherapy plus salvage auto-HCT. Response rates were complete response (CR) plus near CR, 11%; partial response, 79%; overall response rate, 90%. Kaplan-Meier estimates of median progression-free survival (PFS) and overall survival (OS) from time of salvage auto-HCT were 12.3 and 31.7 months, respectively. Median OS from the time of diagnosis was 75 months. Ten patients (23%) experienced grade 3 or higher nonhematologic toxicity after the salvage auto-HCT. One patient died within 100 days, for a treatment-related mortality of 2%.

The investigators concluded: “In selected myeloma patients, a second auto-HCT for salvage therapy is well tolerated, with acceptable toxicity. The overall response rate and PFS are comparable to other salvage regimens.”

Abstract


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs